Ownership and insider activity for Kezar Life Sciences, Inc. (KZR): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Kezar Life Sciences, Inc. is a United States-based clinical-stage biopharmaceutical company focused on identifying and advancing novel small molecule therapies. Its mission is to address significant unmet medical needs in both immune-mediated diseases and various forms of cancer. The company's most advanced experimental drug is KZR-616, a specialized immunoproteasome inhibitor.
Price
| Price | $7.29 |
| Market Cap | $54M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $9.7M | $51.0M | $24.2M | $15.0M | $21.2M | $62.9M | $40.5M | $35.5M | $41.7M | $71.9M |
| Short-term Investments | 0 | 0 | $83.2M | $63.3M | $119.2M | $145.5M | $236.1M | $165.9M | $90.5M | 0 |
| Receivables | 0 | 0 | 0 | $642000 | $766000 | 0 | 0 | $2.3M | $424000 | $1.9M |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $10.5M | $52.3M | $109.8M | $81.1M | $144.8M | $211.7M | $285.7M | $206.9M | $137.5M | $75.7M |
| Property, Plant & Equipment | $862000 | $1.5M | $4.6M | $8.1M | $6.7M | $6.0M | $13.2M | $8.7M | $4.8M | $915000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $11.4M | $54.2M | $114.7M | $89.5M | $151.8M | $217.9M | $299.6M | $221.2M | $144.7M | $76.6M |
| Accounts Payable | $466000 | $547000 | $193000 | $823000 | $2.4M | $2.0M | $2.5M | $8.3M | $3.7M | $507000 |
| Short-term Debt | 0 | 0 | 0 | $900000 | $1.0M | 0 | 0 | 0 | $5.2M | 0 |
| Total Current Liabilities | $651000 | $1.5M | $3.3M | $6.0M | $6.4M | $8.2M | $11.0M | $17.7M | $20.3M | $6.6M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | $9.6M | $9.8M | $10.1M | $5.1M | 0 |
| Total Liabilities | $28.9M | $79.9M | $5.9M | $11.5M | $10.9M | $21.1M | $29.7M | $33.7M | $27.8M | $6.6M |
| Retained Earnings | -$17.5M | -$26.0M | -$49.2M | -$84.3M | -$126.0M | -$180.7M | -$248.9M | -$350.8M | -$434.5M | -$490.5M |
| Total Equity | -$17.4M | -$25.7M | $108.8M | $78.0M | $141.0M | $196.9M | $269.9M | $187.6M | $116.9M | $70.1M |
| Total Debt | 0 | 0 | 0 | $6.4M | $5.5M | $14.0M | $21.3M | $18.9M | $16.2M | $2.3M |
| Net Debt | -$9.7M | -$51.0M | -$107.4M | -$71.8M | -$135.0M | -$194.3M | -$255.3M | -$182.4M | -$116.1M | -$69.6M |
| Working Capital | $9.8M | $50.8M | $106.5M | $75.1M | $138.4M | $203.4M | $274.7M | $189.2M | $117.2M | $69.2M |
Financial Health
| Debt / Equity | 0.02 |
| Current Ratio | 24.46 |
| Piotroski F-Score | 5 |
| Altman Z-Score | -5.93 |
Profitability
| Return on Equity | -79.96% |
| Return on Invested Capital | -72.20% |
| Return on Assets | -73.11% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: CCCC · CRNX · ERAS · EWTX · REPL · SRRK · STRO
Explore sector: Healthcare · Biotechnology
More sections of KZR: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks